3D High Resolution Magnetic Resonance Fingerprinting for Prostate Cancer

项目摘要摘要 其目标是使用快速、准确的方法来客观准确地识别和描述前列腺癌 定量磁共振成像(MRI)方法。病人的护理标准 被怀疑患有前列腺癌的评估是对整个腺体进行系统抽样， 12个活检核心，在影像上没有发现疑似癌症的病灶。当前的定性 虽然磁共振图像大多成功地突出了前列腺癌，但看起来可能不同于 扫描仪到扫描仪，甚至当在同一扫描仪上重复时。这种可变性增加了复杂性 对发现癌症和辨别癌症的已经主观的解释过程 临床上有意义的惰性疾病。因此，更健壮和标准化的MRI方法可以 需要检测和鉴定具有临床意义的前列腺癌。 该项目计划解决这一问题，具体目标如下： (1)将开发和优化用于前列腺的快速高分辨率3D MRF采集 通过创新缩小视场成像、3D笛卡尔采样和 MRF中的高级重建。计划中的MRF收购将实现准确的T1和T2 以各向同性亚毫米分辨率(0.8mm3)在前列腺上进行标测 采集时间不到5分钟。 (2)使用基于MRF的T1和T2图合成的对比度加权图像将取代 用于前列腺癌检测的常规定性图像。 (3)基于MRF的具有表观扩散系数的T1和T2将被验证用于肿瘤的分离 区别于非癌症和不同级别的癌症。 (4)来自MRF的前列腺癌的显微结构特征将提供关于 亚体素成分(上皮、间质、管腔及其体积分数)以揭示隐匿性 此外，还可以对癌症进行分类，并能够区分不同级别的癌症。 该项目将通过提供可重复和可重复的非侵入性成像来促进前列腺成像 定量成像指标。这些创新将取代传统的对比度加权 成像采用单一快速高分辨率标准MRF协议，提供了一种客观 前列腺癌的识别和分级，完善前列腺癌的分类 使用微结构特征，从而减少不必要的活组织检查并促进适当的 治疗选择。

Project Summary Abstract The goal is to identify and characterize prostate cancer objectively and accurately using a rapid quantitative Magnetic Resonance Imaging (MRI) approach. The standard-of-care in patients being evaluated for suspicion of prostate cancer is systematic sampling of the entire gland with 12 biopsy cores, without an identified focus suspicious for cancer on imaging. Current qualitative MR images, while mostly successful in highlighting prostate cancer, may look different from scanner to scanner, or even when repeated on the same scanner. This variability adds complexity to an already subjective interpretive process of detecting cancer and discriminating between clinically significant and indolent disease. Thus, more robust and standardized MRI methods to detect and characterize clinically significant prostate cancer are needed. This project plans to address this issue with following specific aims: (1) A rapid high-resolution 3D MRF acquisition will be developed and optimized for prostate cancer assessment by innovating reduced field-of-view imaging, 3D Cartesian sampling, and advanced reconstruction in MRF. The proposal MRF acquisition will enable accurate T1 and T2 mapping over the prostate gland with an isotropic submillimeter resolution (0.8 mm3) in an acquisition time of less than 5 minutes. (2) Contrast-weighted images synthesized using MRF-based T1 and T2 maps will replace conventional qualitative images for detecting prostate cancer. (3) MRF-based T1 and T2 with apparent diffusion coefficient will be validated to separate cancer from non-cancer and differentiate cancers with different grades. (4) Microstructural signatures of prostate cancer derived from MRF will provide information about subvoxel components (epithelium, stroma, lumen, and their volume fractions) to reveal occult cancers and enable the discrimination of different grades of cancer. This project will advance prostate imaging by providing reproducible and repeatable non-invasive quantitative imaging metrics. These innovations will replace conventional contrast-weighted imaging with a single rapid high-resolution standard MRF protocol, provide an objective identification of prostate cancer and grading, and improve the classification of prostate cancer using microstructural signatures, thus reducing unnecessary biopsies and facilitating appropriate treatment selection.